Zhejiang Hisun Pharmaceutical Co Ltd (600267) - Total Liabilities
Based on the latest financial reports, Zhejiang Hisun Pharmaceutical Co Ltd (600267) has total liabilities worth CN¥4.62 Billion CNY (≈ $675.70 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Zhejiang Hisun Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Zhejiang Hisun Pharmaceutical Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Zhejiang Hisun Pharmaceutical Co Ltd total assets.
Zhejiang Hisun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Hisun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BWP Trust
AU:BWP
|
Australia | AU$1.08 Billion |
|
Central China Securities Co Ltd
SHG:601375
|
China | CN¥42.83 Billion |
|
Malaysian Pacific Industries
KLSE:3867
|
Malaysia | RM956.47 Million |
|
Domain Holdings Australia Ltd
AU:DHG
|
Australia | AU$369.52 Million |
|
King’s Town Bank
TW:2809
|
Taiwan | NT$310.19 Billion |
|
China Automotive Engineering Research Institute Co Ltd
SHG:601965
|
China | CN¥3.45 Billion |
|
Resolute Mining Ltd
AU:RSG
|
Australia | AU$498.14 Million |
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
Germany | €5.01 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Zhejiang Hisun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Zhejiang Hisun Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Hisun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Hisun Pharmaceutical Co Ltd (1997–2025)
The table below shows the annual total liabilities of Zhejiang Hisun Pharmaceutical Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥6.20 Billion ≈ $907.24 Million |
-16.14% |
| 2024-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
-20.19% |
| 2023-12-31 | CN¥9.26 Billion ≈ $1.36 Billion |
-11.33% |
| 2022-12-31 | CN¥10.45 Billion ≈ $1.53 Billion |
-13.14% |
| 2021-12-31 | CN¥12.03 Billion ≈ $1.76 Billion |
-4.56% |
| 2020-12-31 | CN¥12.60 Billion ≈ $1.84 Billion |
-8.56% |
| 2019-12-31 | CN¥13.78 Billion ≈ $2.02 Billion |
-4.78% |
| 2018-12-31 | CN¥14.48 Billion ≈ $2.12 Billion |
+5.19% |
| 2017-12-31 | CN¥13.76 Billion ≈ $2.01 Billion |
+8.19% |
| 2016-12-31 | CN¥12.72 Billion ≈ $1.86 Billion |
+15.53% |
| 2015-12-31 | CN¥11.01 Billion ≈ $1.61 Billion |
+21.87% |
| 2014-12-31 | CN¥9.03 Billion ≈ $1.32 Billion |
+12.72% |
| 2013-12-31 | CN¥8.01 Billion ≈ $1.17 Billion |
+49.20% |
| 2012-12-31 | CN¥5.37 Billion ≈ $786.00 Million |
+47.67% |
| 2011-12-31 | CN¥3.64 Billion ≈ $532.27 Million |
+14.48% |
| 2010-12-31 | CN¥3.18 Billion ≈ $464.96 Million |
+14.79% |
| 2009-12-31 | CN¥2.77 Billion ≈ $405.06 Million |
+7.62% |
| 2008-12-31 | CN¥2.57 Billion ≈ $376.38 Million |
+59.90% |
| 2007-12-31 | CN¥1.61 Billion ≈ $235.38 Million |
+4.30% |
| 2006-12-31 | CN¥1.54 Billion ≈ $225.67 Million |
+11.92% |
| 2005-12-31 | CN¥1.38 Billion ≈ $201.63 Million |
+40.92% |
| 2004-12-31 | CN¥977.76 Million ≈ $143.08 Million |
+12.13% |
| 2003-12-31 | CN¥871.96 Million ≈ $127.59 Million |
+16.15% |
| 2002-12-31 | CN¥750.69 Million ≈ $109.85 Million |
+45.84% |
| 2001-12-31 | CN¥514.75 Million ≈ $75.32 Million |
+14.64% |
| 2000-12-31 | CN¥449.01 Million ≈ $65.70 Million |
+6.34% |
| 1999-12-31 | CN¥422.24 Million ≈ $61.79 Million |
+47.02% |
| 1998-12-31 | CN¥287.20 Million ≈ $42.03 Million |
+70.26% |
| 1997-12-31 | CN¥168.68 Million ≈ $24.68 Million |
-- |
About Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of biological and generic drugs in China. The company provides active pharmaceutical ingredients. It also offers its products for anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, and orthopedics treatment; nutrition and healthcare; and oncology, ADC small mol… Read more